FDA Weighs Lower Dosage for Moderna COVID-19 Booster Shot
The FDA is deliberating between approving a booster shot of Moderna’s COVID-19 vaccine at a 50 microgram (mcg) level or at a current 100 mcg level, the latter being the level that make up the first two doses each of the vaccine.
Last week, Cambridge, Mass.-based Moderna announced that it has asked the FDA to evaluate the booster dose at the 50-mcg level. The vaccine is formally known as mRNA-1273.
The company said it expects to submit data to the European Medicines Agency and other international regulatory authorities in the coming days.